Heterogeneous patterns of ER/PR expression in tumors may thus be due to residual transcriptional regulation in response to signals from the tumor microenvironment [9], the menstrual cycle of the patient [10] or after treatment [6]. This evidence concerns the gene ESR1 and neoplasm.